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This study examined D-amphetamine (D-AMPH)-induced displacements of [18F] fallypride in striatal and extrastriatal regions and the
correlations of these displacements with cognition, affect, and sensation-seeking behavior. In all, 14 normal subjects, six females and eight
males (ages 21–32, mean age 25.9 years), underwent positron emission tomography (PET) with [18F]fallypride before and 3 h after a
0.43 mg/kg oral dose of D-AMPH. Levels of dopamine (DA) D2 receptor density were calculated with the reference region method of
Lammerstma. Percent displacements in striatal and extrastriatal regions were calculated for the caudate, putamen, ventral striatum,
medial thalamus, amygdala, substantia nigra, and temporal cortex. Correlations of changes in cognition, affect, and sensation seeking with
parametric images of D-AMPH-induced DA release were computed. Significant displacements were seen in the caudate, putamen,
ventral striatum substantia nigra, and temporal cortex with a trend level change in the amygdala. Greatest displacements were seen in
striatal subdivisionsF5.6% in caudate, 11.2% in putamen, 7.2% in ventral striatum, and 6.6% in substantia nigra. Lesser decrements were
seen in amygdalaF4.4%, temporal cortexF3.7%, and thalamusF2.8%. Significant clusters of correlations of regional DA release with
cognition and sensation-seeking behavior were observed. The current study demonstrates that [18F]fallypride PET studies using oral
D-AMPH (0.43 mg/kg) can be used to study D-AMPH-induced DA release in the striatal and extrastriatal regions in humans, and their
relationship with cognition and sensation-seeking behavior.
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Several brain imaging studies have investigated D-amphe-
tamine (D-AMPH)-induced dopamine (DA) release in the
striatum (Laruelle et al, 1995; Kegeles et al, 1999; Drevets
et al, 2001; Singer et al, 2002; Piccini et al, 2003; Martinez
et al, 2003; Volkow et al, 1994, 2004). However, dopami-
nergic neurotransmission in cortex, thalamus, and limbic
regions is believed to be significantly involved in psychosis,
cognitive function, and psychostimulant drug abuse (Wein-
berger et al, 2001; Stevens, 1991; Kerwin and Murray, 1992;
Goldman-Rakic, 1998; Yasuno et al, 2004; Koob and
Le Moal, 2001). Most, but not all, recent brain-imaging
studies suggest that extrastriatal DA D2 receptors are the
site of antipsychotic drug actions (Farde et al, 1997;
Pilowsky et al, 1997; Bigliani et al, 2000; Xiberas et al,
2001a, b; Kessler et al, 2002; Bressan et al, 2003; Talvik et al,
2001). Extrastriatal dopaminergic neurotransmission is an
important area of research in neuropsychiatric disorders
(Kaasinen et al, 2001; Suhara et al, 2002).
The affinity of currently used DA D2 radioligands such as
[11C]raclopride, 1.2 nM (Hall et al, 1989), and [123I]IBZM,
0.4 nM (Kung et al, 1989), permits accurate measurement
of DA D2 receptor levels only in the striatum, which has
the highest DA D2 receptor levels in brain (Kessler et al,
1993b; Laruelle et al, 1995; Drevets et al, 2001). With the
development of high-affinity radioligands, such as [11C]FLB
457, [123I]epidepride, and [18F]fallypride, it has been
possible to visualize and quantitate levels of striatal and
extrastriatal DA D2/D3 receptors (Kessler et al, 1991, 1992,
1993a; Halldin et al, 1995; Mukherjee et al, 1995). The
striatal uptakes of [11C]FLB 457 and [123I]epidepride are
prolonged (Farde et al, 1997; Olsson et al, 1999; Fujita et al,
1999), making estimation of striatal DA D2/D3 receptor
levels difficult. [18F]fallypride is a benzamide with very
high-affinity for DA D2/D3 receptors, which has been used
to visualize and quantify levels of striatal and extrastriatal
DA D2/D3 receptors using positron emission tomography
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(PET) (Mukherjee et al, 1999, 2002; Rieck et al, 2004).
Although [18F]fallypride has an in vitro KD for the DA D2/D3
receptors similar to that of [123I]epidepride and [11C]FLB
457, it has considerably more rapid washout from striatum,
allowing estimation of DA D2/D3 receptor levels in both
striatal and exrtastriatal regions (Mukherjee et al, 1997;
Kessler et al, 1991; Olsson et al, 1999, 2004; Christian et al,
2004).
SPECT and PET studies of DA D2/D3 receptors performed
before and after a D-AMPH challenge have been used to
study striatal DA release. The decrement in striatal binding
potential (b.p.) or V3
00 for benzamide DA D2/D3 radioligands
following D-AMPH administration in primates has been
shown to be linearly related to the level of D-AMPH-induced
DA release (Laruelle et al, 1997; Breier et al, 1997). In
humans, PET and SPECT studies using either [11C]raclo-
pride or [123I]IBZM have demonstrated D-AMPH (0.3 mg/kg
intravenous)-induced decrements of 7.1–16.1% in striatal
b.p. or V3
00 (Abi-Dargham et al, 1998; Laruelle et al, 1995;
Drevets et al, 2001; Martinez et al, 2003). Recently,
Cardenas, using [11C]raclopride PET, reported that an oral
dose of 30 mg of D-AMPH produced a decrease in striatal
b.p. of 13–18% in humans (Cardenas et al, 2004).
Epidepride with an affinity of 24 pM for the DA D2 receptor
shows virtually no displacement after a 1 mg/kg dose of
D-AMPH (Kessler et al, 1993c; al-Tikriti et al, 1994). Studies
of [11C]FLB 457 with a reported affinity of 20 pM for the DA
D2 receptor (Olsson et al, 1999) have produced conflicting
results regarding its sensitivity to extracellular DA levels
(Chou et al, 2000; Okauchi et al, 2001). Primate studies of
[18F]fallypride, with an affinity of 33 pM for the DA D2
receptor and 31 pM for the DA D3, have reported D-AMPH-
induced decreases in b.p. of 12–36% in the thalamus,
hippocampus, amygdala, and ventral striatum following
0.3–1.0 mg/kg intravenous doses of D-AMPH (Mukherjee
et al, 1997, 2002; Slifstein et al, 2004).
No PET or SPECT studies of D-AMPH-induced DA release
in extrastriatal regions have been reported in humans
although, as discussed above, such studies have been
reported in nonhuman primates (Mukherjee et al, 1997,
2002; Slifstein et al, 2004). The aim of this study was
to assess whether [18F]fallypride can be used to estimate
D-AMPH-induced DA release in striatal and extrastriatal
regions in humans following a 0.43 mg/kg oral dose of
D-AMPH. An oral dose of 0.43 mg/kg of D-AMPH in
comparison to an intravenous dose of 0.2–0.3 mg/kg
produces lesser side effects such as elevated blood pressure,
but similar plasma levels and displacement of [11C]raclo-
pride in striatum (Angrist et al, 1987; Breier et al, 1997;
Cardenas et al, 2004).
METHODS
In all, 14 normal subjects, six females and eight males (ages
21–32 years, mean age of 25.9 years), were recruited by
advertisement. All subjects were right hand dominant and
none were smokers. Exclusion criteria included a history of
psychiatric or neurological condition, a history of severe
concomitant or past medical illness, borderline elevated
blood pressure (135/90), any psychotropic medication usage
for the last 6 months, a history of substance abuse and
dependence, inability to provide informed consent, an IQ
less than 80, and pregnancy or lactation. After an initial
assessment, the study was explained to subjects and
informed consent was obtained. The consent form included
a recommendation for all participants to use adequate birth
control measures during the study. All female subjects
capable of childbearing had pregnancy tests performed 6 h
or less prior to each PET study. All subjects received a
physical and neurological examination, SCID (Williams
et al, 1992), blood chemistries, urine analysis and urine
drug screen, EKG and MRI study. Subjects additionally
completed the Sensation Seeking Scale-Form (Zuckerman
et al, 1978). MRI scans were performed using a GE 1.5 T
scanner with echospeed gradients. Thin-section, high-
resolution, T1-weighted coronal and sagittal IR SPGR
sequences were obtained (TE¼ 3.6, TR¼ 18.9, TI¼ 400,
slice thickness of 1.2–1.4 mm) and an axial T2-weighted
sequence (TE¼ 106, TR¼ 5000, slice thickness of 3 mm)
was obtained as well. Subjects who met the study criteria
were scheduled for PET studies which were performed
using a GE Discovery LS PET scanner; 3-D emission acqui-
sitions and transmission attenuation correction scans were
performed following a 5.0 mCi slow bolus injection of
[18F]fallypride (specific activity greater than 3000 Ci/mmol)
prior to and 3 h following a 0.43 mg/kg oral dose of
D-AMPH. Serial scans were initiated simultaneously with
the bolus injection of [18F]fallypride and were obtained for
approximately 3.5 h. The initial scan sequence was started
coincident with the start of the [18F]fallypride injection and
included the following frames: 8 for 15 s, 6 for 30 s, 5 for
1 min, 2 for 2.5 min, 3 for 5 min, and 3 for 10 min. After the
initial scan sequence, a 10-min transmission scan was
obtained and the subject given a break. At approximately
85–90 min, a second scan sequence of two frames of 25 min
each followed by a second transmission scan were obtained.
The subject was then allowed a second scan break, and at
approximately 165–170 min, a 40-min emission scan
followed by a third transmission scan was obtained. For
the post-D-AMPH study, subjects were instructed to have a
light breakfast on the day of the scan, that is, a single cup of
coffee, cold cereal, and/or bread, which was ingested
approximately 4 h prior to D-AMPH administration. Phy-
siological measures (blood pressure, heart rate, tempera-
ture, and respirations) were monitored throughout the
study and a brief neurological examination performed.
Blood samples were collected for determination of plasma
levels of D-AMPH at 1, 3, and 5 h following D-AMPH
administration. The plasma samples were analyzed using a
modification of the method of Campins-Falco et al, 1996.
Briefly, 1.0 ml plasma samples, following addition of the
internal standard B-phenylethylamine, were made basic
and the amines isolated and derivatized on Waters Sep-Pak
C-18 cartridge using 1,2-naphthoquinone-4-sulphate (NQS)
as described by Campins-Falco. Following washing, the
derivatized amines were eluted with acetonotrile : water
(1 : 1), the volume reduced under vacuum, and the eluate
analyzed by HPLC. The peaks corresponding to derivatized
amphetamine and NQS were separated using a 7 53 mm
Hypersil BDS ‘Rocket’ column (Alltech Assoc.) and
quantitated by UV analysis at 450 nM.
Serial PET scans and thin-section T1-weighted MRI scans
were coregistered to each other using a mutual information
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rigid body algorithm (Pluim et al, 2001). Regions of interest
were delineated for the right and left caudate, putamen,
ventral striatum, amygdala, substantia nigra, the medial
thalami, and temporal cortex on MRI scans of the brain (see
Figures 1 and 2) by a neuroradiologist experienced in PET
data analysis (RMK) and automatically transferred to both
the pre- and post-D-AMPH PET studies. The ventral
striatum was defined according to criteria of Mawlawi
et al, 2001. The substantia nigra was delineated based on
landmarks from the Schaltenbrand atlas (Schaltenbrand and
Wahren, 1977); the substantia nigra is located in the ventral
midbrain posteromedial to the cerebral peduncles from the
superior aspect of the interpeduncular fossa approximately
9 mm below the ACPC line to 16 mm below the ACPC line.
These regions of interest were transferred to the coregis-
tered PET scans and regional DA D2 receptor b.p.’s were
calculated using the reference region method (Lammertsma
et al, 1996). Percent displacements were calculated for each
region of interest. Parametric images of DA D2/D3 receptor
density and percent displacement were calculated on a
pixel-by-pixel basis using the reference region method.
Images were coregistered across subjects using an elastic
deformation algorithm (Rohde et al, 2003). Approximately
60 min after D-AMPH administration (and at the equivalent
point in time on non-drug administration days), subjects
began a 75-min neuropsychological battery. The battery
included measures of attentionFStroop task (Stoelting Co.,
2000), information-processing speedFDigit Symbol Cod-
ing and Symbol Search (Wechsler, 1997), spatial working
memory (Park et al, 1999), and affectFPositive Affect
Negative Affect Scale (Watson et al, 1988). In order to
minimize the practice effects, all tests were either presented
using parallel forms, or utilized random order presentation
of stimuli. One male subject was color-blind; although he
completed all tests, he was excluded from analysis of the
Stroop task that requires color processing. A second male
subject had a disrupted spatial working memory trial during
the baseline study and he was excluded from the working
memory analysis.
To test the effects of D-AMPH on [18F]fallypride binding,
we performed a repeated-measures ANOVA implemented in
the General Linear Model module of SPSS 11.5 (SPSS Inc.,
IL). The model used had three within-subject factors,
condition (baseline, D-AMPH), region, and laterality. Paired
two-tailed t-tests and Wilcoxon signed-rank tests were
performed to delineate the source of significant differences
on the ANOVA. Bonferroni correction for multiple compari-
sons were performed. Correlations of changes in cognition,
affect, and sensation seeking with parametric images of
[18F]fallypride displacement were made using a Pearson
Figure 1 [18F]fallypride PET scans obtained at baseline in a normal subject at (a) the level of the thalamus showing highest uptake in medial thalamus;
(b) at the level of the midbrain showing uptake in the substantia nigra in the ventral midbrain and in the colliculi dorsally in the midbrain, (c) at the level of
the uncus showing uptake in the amygdala, and (d) through the inferior temporal cortex showing high uptake in the pituitary and temporal cortex.
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product moment correlation and significance assessed
using two tailed t-tests. Correction for multiple within-
image comparisons was made using the method of Forman
et al (1995) as implemented in the Alpha-Sim program of
the AFNI analysis program. This was utilized as the image
data violated the uniformity of variance assumption of SPM.
After correction for multiple within-image comparisons,
significant clusters were corrected for multiple behavioral
tests using a Bonferroni correction.
RESULTS
Repeated-measures ANOVA using condition, region, and
laterality as factors revealed significant effects of region
(F¼ 415.5, po0.00000008) consistent with the large differ-
ences seen in regional b.p.’s (see Table 1, Figures 1 and 2),
and a main effect of laterality (F¼ 19, po0.001) reflecting
higher b.p.’s in the left temporal cortex, medial thalamus,
and ventral striatum, but not caudate or putamen. There
was a robust effect of condition due to a decrease in
[18F]fallypride b.p.’s following D-AMPH administration
(F¼ 48.5, p¼ 0.00001) as well as a significant condition by
region interaction consistent with varying decreases across
regions (F¼ 16.99, p¼ 0.0037). In contrast, there were no
significant interactions of condition by laterality (F¼ 0.36,
p40.1) or condition by region by laterality (F¼ 0.56,
p40.1). Given the lack of a laterality effect, regional
displacements were averaged across the right and left
regions of interest.
The greatest D-AMPH-induced displacements of [18F]fall-
ypride were seen in the striatum and substantia nigra, while
lower levels of displacement were seen in the amygdala,
temporal cortex, and thalamus (see Table 1). The mean
displacement in the putamen was 11.22%, while the mean
displacements in the ventral striatum and caudate were 7.23
and 5.57%, respectively. The mean displacement in the
substantia nigra was 6.64% similar to that seen in caudate
and ventral striatum. Lower levels of displacement were
seen in the amygdalaF4.36%, medial thalamusF2.84%,
and temporal cortexF3.67%. Using paired two-tailed
t-tests with a Bonferroni correction for multiple comparisons,
displacements were significant in all regions except the
medial thalamus which achieved a trend level (p¼ 0.07).
The significance of regional displacements was also
evaluated using the Wilcoxon signed ranks test (two-tailed)
Figure 2 Parametric images of DA D2 receptor density coregistered with MRI images windowed to demonstrate [18F]fallypride-b.p.’s in (a) the anterior
and ventral striatum on a coronal image, (b) the medial thalamus on an axial image, (c) the substantia nigra, colliculi, and temporal cortex on an axial image
through the midbrain, and (d) the amygdala and temporal cortex on an axial image through the uncus of the temporal lobes.
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with a Bonferroni correction; displacements remained
significant in the caudate (po0.03), putamen (p¼ 0.007),
ventral striatum (po0.014), substantia nigra (p¼ 0.014),
and temporal cortex (po0.03), but fell to a trend level in the
amygdala (p¼ 0.06).
Correlations of changes in cognition with parametric
images of DA release following D-AMPH administration
showed a number of significant clusters of correlations with
measures of attention and speed of cognitive processing
(see Figures 3 and 4). Changes in performance on the Digit
Symbol Coding, a test of attention, and speed of cognitive
processing, were significantly correlated with a cluster
centered in the right ventral striatum, but involving the
right and left ventral striatum and basal forebrain
(po0.006, corrected for multiple-image comparisons and
behavioral tests) due to significant negative correlations
Table 1 D-AMPH-Induced Decrements in Regional Binding Potentials (Means7SD) and Levels of Significance Corrected for Multiple
Comparisons Using Paired 2-Tailed t-Tests and Wilcoxon Signed-Rank Test in Parenthesis
Region Baseline BP Post-D-AMPH BP Percent displacement Significance level
Caudate 33.0272.09 31.1772.35 5.5774.60 0.005 (0.03)
Putamen 38.3272.64 33.9872.36 11.2274.34 0.000004 (0.007)
Ventral striatum 21.8272.07 20.1971.55 7.2375.29 0.002 (0.014)
Substantia nigra 2.5770.21 2.4070.22 6.6474.21 0.0004 (0.014)
Medial thalamus 4.5870.50 4.4570.46 2.8473.66 0.07 (0.23)
Amygdala 3.4870.44 3.3270.44 4.3673.40 0.008 (0.06)
Temporal cortex 1.6470.26 1.5870.26 3.6773.65 0.02 (0.03)
Figure 3 Significant clusters of correlations between D-AMPH-induced DA release and (a) digit symbol coding (ventral striatum and basal forebrain),
(b) symbol search (left ventral putamen), and (c, d) stroop task (left temporal and insular cortex, right temporal cortex).
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ranging from r¼0.53 to 0.82 (see Figure 3). A
significant cluster of correlations on performance on the
symbol search task, a measure of speed of cognitive
processing, was observed in the left ventral putamen
(po0.05, corrected for both multiple-image comparisons
and behavioral tests) due to significant negative correla-
tions, r¼0.54 to 0.75 (see Figure 3). Significant clusters
of correlations of performance on the Stroop task, a test of
attention, were seen with the left temporal cortex and insula
(po0.02, corrected for multiple-image and behavioral
comparisons), and with a second cluster involving the right
lateral and inferior temporal cortex (p¼ 0.01, corrected for
multiple-image and behavioral comparisons) (see Figure 3);
both clusters were due to significant negative correlations,
r¼0.53 to 0.92. No significant clusters of correlations
were seen with changes in spatial working memory.
Sensation-seeking behavior demonstrated a number of
significant clusters of correlations with D-AMPH-induced
DA release (see Figure 4). These included a cluster involving
the anterior cingulate with greatest extent in the pre and
subgenual cingulate (p¼ 0.04, corrected for multiple–image
comparisons and behavioral tests), a cluster in the left
insula and temporal cortex (po0.006, corrected for multi-
ple-image comparisons and behavioral tests), and a cluster
in the left thalamus which extended into the left hippo-
campus/medial temporal cortex (po0.006, corrected for
multiple-image comparisons and behavioral tests). These
clusters reflected significant negative correlations in these
regions, with r’s ranging from 0.53 to 0.91. No
significant clusters were observed for changes in positive
affect with DA release.
Plasma D-AMPH levels were 0.4570.26 (SD) ng/ml at 1 h
after administration, 0.4470.22 at 3 h, and 0.3570.13 at 5 h.
There were no significant correlations of plasma D-AMPH
levels at 1, 3, or 5 h with decrements in putamenal b.p.’s.
DISCUSSION
The results of this study demonstrate significant displace-
ments of [18F]fallypride by DA released by oral D-AMPH
in the striatum, substantia nigra, and cortex, with a trend
level change in the amygdala. The magnitude of striatal
displacement is similar to that reported with either
[123I]IBZM or [11C]raclopride using either oral (30 mg) or
intravenous doses (0.3 mg/kg) of D-AMPH. [123I]IBZM
SPECT studies of D-AMPH-induced displacements report
decrements in the striatum of 7–9% in normal subjects
following an intravenous dose of 0.3 mg/kg (Abi-Dargham
et al, 2003, 2004; Laruelle et al, 1996; Kegeles et al, 1999).
Figure 4 Significant clusters of correlations of sensation seeking with D-AMPH-induced DA release in (a) anterior cingulate, (b) left temporal cortex, (c, d)
left thalamus extending into the left hippocampus.
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[11C]raclopride PET studies of D-AMPH (0.3 mg/kg, intra-
venous)-induced displacements of approximately 8–16% in
striatal subdivisions have reported decrements in the dorsal
putamen, 4–6% in the caudate, and 15% in the ventral
striatum (Martinez et al, 2003; Drevets et al, 2001). The
decrements seen in the caudate and dorsal putamen in the
current study are similar to those reported with [11C]raclo-
pride studies using intravenous D-AMPH, but are consider-
ably lower in the ventral striatum. The only previous PET
study which employed a comparable oral D-AMPH dose,
that is, 30 mg, to that used in the current study, reported a
striatal decrement of 13% at 2 h post-D-AMPH administra-
tion, comparable to the results in the current study in which
scanning commenced at 3 h post-injection. The results of
the current study indicate that [18F]fallypride has a
sensitivity similar to D-AMPH-released DA in comparison
to [11C]raclopride in the dorsal caudate and putamen.
Although these results are consistent with primate studies
(Slifstein et al, 2004), they are at variance with modeling
studies suggesting that the magnitude of D-AMPH induced
displacement decreases with ligands having b.p. greater
than 10 (Endres and Carson, 1998).
The difference in ventral striatal displacements seen
between the current and previous studies of Martinez et al
(2003) and Drevets et al (2001) may be related to the
different routes of administration. Previous studies of oral
vs intravenous methylphenidate (Volkow et al, 2004) have
shown that oral compared to intravenous methylphenidate
administration produces slower increases in brain methyl-
phenidate levels, comparable peak brain levels, comparable
levels of dorsal striatal DA release, but significantly less
positive reinforcing effects. Positive reinforcing effects were
significantly and positively correlated with dorsal striatal
DA release following intravenous administration of methyl-
phenidate, but no correlation was seen following oral
administration. The ventral striatum has been shown to
mediate the euphorogenic effects of intravenous D-AMPH in
humans (Drevets et al, 2001). The lesser D-AMPH-induced
displacement seen in the ventral striatum in the current
study may reflect different regulation of dorsal vs ventral
striatal DA release in response to differing rates of brain
uptake of DA-releasing drugs, and may be the physiological
basis for the lesser positive reinforcing effects of oral vs
intravenous psychostimulant drugs. It is noteworthy that no
significant correlation cluster of positive affect with DA
release was seen for the group as a whole in the current
study analogous to the results seen with oral methylpheni-
date, another psychostimulant drug which increases extra-
cellular DA levels (Volkow et al, 2004). Additional studies
are needed to confirm these results and to evaluate the
mechanism by which such differential regulation occurs.
Alternative explanations for the difference in ventral
striatal displacements could include differences in methods
and inaccuracies in image registration. To make the results
comparable to the study of Martinez et al, 2003, we used the
same anatomic criteria for delineation of the ventral
striatum as used in that study (Mawlawi et al, 2001). The
resolution of the scanners used in all the current and
previous studies of Drevets and Martinez is similar (Town-
send et al, 1998). The algorithms used for coregistration in
this study have been shown to have registration errors of
1.1 mm in phantom studies and 2.6 mm in previous studies
of PET/MR coregistration using an older PET scanner with
6–8 mm resolution (West et al, 1997; Lavely et al, 2004); the
accuracy of coregistration is demonstrated in the relatively
small standard deviations, 8–9% of the means, seen in
[18F]fallypride b.p.’s in small structures such as the ventral
striatum and substantia nigra. An example of PET/MR
coregistration is shown in Figure 2. The difference in
apparent ventral striatal DA release is probably not due to
methodological factors.
D-AMPH produced a mean displacement of 6.65% in the
substantia nigra, which is similar to that seen in striatum.
This is surprisingly high taking into consideration that
extracellular DA levels at baseline and following D-AMPH
administration are approximately 10% of that seen in the
striatum (Gerhardt et al, 2002). In the substantia nigra, DA
D2 receptors are autoreceptors which are localized on the
dendrites of dopaminergic neurons (Sesack et al, 1994) and
are in the high-affinity agonist state, while in the striatum
they are in both the high- and low-affinity state. It has been
estimated that approximately 40% of striatal DA D2
receptors are in the high-affinity agonist state (Ginovart
et al, 1997; Laruelle et al, 1997; Laruelle, 2000). The b.p. of
the substantia nigra is approximately 10% of that of the
striatum (see Table 1). Endres has suggested that the
sensitivity of benzamide radioligands to extracellular DA
levels is greatest at a b.p. of 3–10, with decreasing sensitivity
above this range (Endres and Carson, 1998). These factors
may be responsible, at least in part, for the surprisingly high
D-AMPH-induced displacement of [18F]fallypride in the
substantia nigra. While the substantia nigra is a small
structure whose apparent receptor levels are diminished by
partial voluming, the borders of the substantia nigra are not
adequately delineated on MRI studies, making implementa-
tion of a partial volume correction problematic. The value
of a partial volume correction for D-AMPH-induced
decrements in regional b.p.’s has been evaluated by Slifstein
in nonhuman primates (Slifstein et al, 2004), who found
significant spillover of striatal counts into extrastriatal
regions, but no significant effect of a partial volume
correction on the change in V3
00 in the striatum and
extrastriatal regions.
It has been previously hypothesized that D-AMPH-
released synaptic DA is responsible for displacement of
benzamide radioligands in striatum (Laruelle, 2000). There
are a number of studies which suggest that dopaminergic
neurotransmission in extrastriatal regions is largely
mediated by a volume or extrasynaptic mode. In the
substantia nigra and VTA, DA release appears to be largely
mediated by reverse transport by the DA transporter
(Falkenburger et al, 2001). The lack of synaptic specializa-
tions in the substantia nigra suggests that somatodendritic
DA release does not rely on typical synaptic neurotransmis-
sion (Heeringa and Abercrombie, 1995). As DA D2 receptors
are largely extrasynaptic in the substantia nigra (Sesack
et al, 1994; Yung et al, 1995), it has been suggested that
dopaminergic neurotransmission in the substantia nigra
may be mediated by volume transmission rather than a
synaptic mode (Fuxe et al, 2005; Cragg et al, 2001; Cragg
and Greenfield, 1997). Previous studies of DA release and
diffusion in the cortex and amygdala indicate that cortical
and amygdalar dopaminergic neurotransmission is
mediated largely via a volume mode (Garris and Wightman,
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1994; Fuxe et al, 2005). Given these observations, the D-
AMPH-induced displacements seen in the substantia nigra,
amygdala, and temporal cortex are likely due, at least in
part, to DA displacement of [18F]fallypride at extrasynaptic
DA D2 receptors.
The magnitude of D-AMPH-induced displacements of
[18F]fallypride is lower in the temporal cortex, amygdala,
and medial thalamus than in the striatum, that is, 2.84–4.36
vs 5.57–11.22%. This is consistent with microdialysis studies
demonstrating a 10-fold lower level of baseline extracellular
DA in the cortex and amygdala and 4–5-fold lesser increases
in extracellular DA levels in these regions following D-
AMPH administration (Moghaddam et al, 1993; Garris and
Wightman, 1994). The greater displacements observed in
primate [18F]fallypride studies are likely due to the higher
doses of D-AMPH administered, different routes of admini-
stration, effects of anesthesia, and species differences
(Slifstein et al, 2004; Narendran et al, 2004; Tsukada et al,
1999a, b; 2002).
In the current study, D-AMPH was administered approxi-
mately 180 min prior to the injection of [18F]fallypride for a
number of reasons. The study of Cardenas demonstrated no
diminution in displacement of [11C]raclopride from 3 to 6 h
after D-AMPH administration. As the current and previous
results (Angrist et al, 1987) show, the plasma levels of
D-AMPH remain reasonably constant from 3 to 5 h after oral
D-AMPH administration. A 3 h delay in [18F]fallypride
administration following oral D-AMPH administration
allows neuropsychological testing and scanning with a
single dose of D-AMPH, permitting a within-subject
comparison of change in cognition and affect with regional
DA release. There are a number of factors which may affect
apparent D-AMPH displacements, including changes in
cerebral blood flow, and D-AMPH induced changes in the
cerebellar distribution volume of [18F]fallypride. The effects
of D-AMPH on blood flow are minimal by 3 h (Price et al,
2002); Slifstein et al, (2004) has presented simulations
showing that changes in cerebral blood flow would have
only minimal effects on D-AMPH-induced displacements of
[18F]fallypride. It is unlikely that changes in cerebral blood
flow are responsible for the apparent displacements. D-
AMPH does not significantly affect the cerebellar distribu-
tion volume of [18F]fallypride in nonhuman primates. In
addition, the highly significant differences in regional
displacements seen in the current study suggest that a
change in cerebellar distribution volume is not a major
factor in the regional displacements. Further studies are
needed to examine this issue.
We examined correlations of changes in neurocognitive
functions, that is, attention, speed of cognitive processing,
and spatial working memory, positive affect, as well as
sensation-seeking behavior with D-AMPH-induced DA
release using parametric image analyses. These behaviors
have previously been shown to be modulated by cerebral
dopaminergic neurotransmission (Rogers, 1986; Piazza
et al, 1991; Hooks et al, 1994; Lawrence et al, 1998; Shah
et al, 1997; Mehta et al, 1999; Marinelli and White, 2000;
Drevets et al, 2001; Abi-Dargham et al, 2003). Although only
a relatively small group of normal subjects was examined,
significant clusters of correlations, corrected for both
multiple-image and behavioral comparisons, were seen with
multiple measures of attention and speed of cognitive
processing, as well as with sensation seeking. These
significant correlations of DA-modulated behaviors with
regional DA release in the striatal and extrastriatal regions
suggest that the apparent variability seen across subjects in
regional DA release may reflect intersubject differences in
DA release and not simply image-related noise. This is
consistent with a recent PET study finding decreases in
frontal and temporal DA D2 receptor availability during
performance of attentional and working memory tasks
(Aalto et al, 2005). These results suggest that [18F]fallypride
PET studies can be used to study the relationship between
regional DA release in the striatum and extrastriatal regions
and neuropsychological function.
The lack of significant clusters of correlations with
positive affect and spatial working memory, as well as the
differences between the current study and that of Leyton
et al (2002) in regard to novelty seeking, may be due to a
number of factors. First, only a small group was examined
which has limited power given the size and variability of
the D-AMPH-induced decrements in [18F]fallypride b.p.’s.
As noted above, Volkow et al, (2004) did not observe
correlations of the positive reinforcing effects of methyl-
phenidate with dorsal striatal DA release after oral
administration, although such a correlation was seen with
intravenous administration. The correlation coefficient
observed by Abi Dargham with D-AMPH-induced DA
release with positive affect in a large group of subjects, that
is, 60, was approximately 0.37. In addition, the smaller
D-AMPH-induced displacement in the ventral striatum
compared to previous [11C]raclopride PET studies (Drevets
et al, 2001; Martinez et al, 2003) may limit the ability to
demonstrate a significant correlation with change in
positive affect, although the smaller standard deviation in
the ventral striatum in the current study (5.29 vs 10.6 and
11.8%) may moderate this limitation. The oral route of
administration and the small size of the correlation with
positive affect seen in the largest group reported to date
may limit the ability of the current study to detect
correlations with positive affect. Frontal cortical dopami-
nergic neurotransmission has been shown to modulate
spatial working memory (Sawaguchi and Goldman-Rakic,
1991). The low b.p. of [18F]fallypride in the frontal cortex
(Mukherjee et al, 2002) as well as the small number of
subjects in this study may limit the ability of [18F]fallypride
PET studies to detect D-AMPH-induced DA release in the
frontal cortex. In regard to sensation-seeking and novelty-
seeking behaviors, Leyton reported a significant positive
correlation between D-AMPH-induced ventral striatal DA
release, and novelty seeking as measured on the TPQ.
Leyton examined eight male subjects using a lower oral dose
of D-AMPH. Interestingly, no displacement of [11C]raclo-
pride from the caudate or putamen was observed although
levels of ventral striatal DA release similar to that seen in
the current study were observed. While the reasons for the
discrepancies between the two studies are not clear, the use
of a different rating instrument, a lower dose of D-AMPH
which did not appear to affect the dorsal striatum, and the
use of only male subjects may be some of the factors
responsible for this discrepancy. We have found gender
differences in a number of correlations of behaviors with
regional DA release (Riccardi et al, 2005). Correlation of
region of interest data showed a correlation coefficient of
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0.898, p¼ 0.006 for sensation seeking with left ventral
striatal DA release in male subjects, but a correlation
coefficient of 0.713 in female subjects. This difference was
significant at the p¼ 0.005 level. When male and female
subjects are grouped together, no significant correlation is
seen. As we have demonstrated (Riccardi et al, 2005), sex
differences need to be considered in evaluating regional DA
release and its relationship to behavior.
In conclusion, the results of this study demonstrate the
feasibility of using [18F]fallypride PET studies with oral
D-AMPH to study DA release in extrastriatal and striatal
regions, as well as the relationship of regional DA release to
neuropsychological function. This method should allow
study of DA release in schizophrenia, psychostimulant drug
abuse, attention deficit disorder, depression, as well as other
disorders.
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